| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Mink Therapeutics, Inc. (INKT) has 7 insiders with recent SEC Form 4 filings, including 3 buys and 7 sells. INKT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 53.1K | $650.9K | - | |
| CEO | 50.0K | $612.5K | - | |
| Dir | 22.9K | $280.8K | - | |
| Dir | 22.6K | $277.5K | - | |
| Dir | 22.0K | $269.1K | -1,500 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Ryan Barbara | Director | Sell | 1,500 | $12.76 | $19,141.25 | -3.2% | - | - | |
| Mar 10, 2026 | Ryan Barbara | Director | Sell | 1,500 | $14.70 | $22,051.76 | -1.7% | - | - | |
| May 5, 2023 | Armen Garo H49 | Director | Sell | 100,000 | $0.95 | $94,850.00 | -5.1% | +8.9% | -38.0% | |
| May 2, 2023 | Armen Garo H49 | Director | Buy | 100,000 | $0.95 | $94,850.00 | +5.3% | +110.1% | +7.0% | |
| Jul 19, 2022 | Wiinberg Ulf52 | Director | Buy | 20,000 | $1.38 | $27,646.30 | +3.6% | +38.2% | +33.3% |